Beacon Biosignals completed the acquisition of Clevemed.

Beacon Biosignals, the global at-home EEG and AI-powered neurotechnology, completed the acquisition of Clevemed, a home sleep testing technology and services. Financial terms were not disclosed. “There is a lot we can learn from each other to expand and enhance our service offerings, including bringing the power of Beacon Biosignals AI-driven algorithms to CleveMed’s existing devices and offerings,” Jacob Donoghue, Beacon Biosignals CEO and Co-Founder.